KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $178.8 million.

  • Pacira BioSciences' Free Cash Flow rose 14.32% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.2 million, marking a year-over-year decrease of 35.82%. This contributed to the annual value of $178.8 million for FY2024, which is 28.15% up from last year.
  • As of FY2024, Pacira BioSciences' Free Cash Flow stood at $178.8 million, which was up 28.15% from $139.5 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Free Cash Flow registered a high of $178.8 million during FY2024, and its lowest value of $39.2 million during FY2020.
  • In the last 3 years, Pacira BioSciences' Free Cash Flow had a median value of $139.5 million in 2023 and averaged $144.5 million.
  • As far as peak fluctuations go, Pacira BioSciences' Free Cash Flow tumbled by 35.01% in 2020, and later skyrocketed by 103.54% in 2021.
  • Pacira BioSciences' Free Cash Flow (Yearly) stood at $39.2 million in 2020, then spiked by 103.54% to $79.9 million in 2021, then soared by 44.27% to $115.2 million in 2022, then increased by 21.09% to $139.5 million in 2023, then grew by 28.15% to $178.8 million in 2024.